The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Topic: Cardiovascular disease - Primary Care

Thursday, 08 August 2019
The benefits of lipid modification therapy in reducing cardiovascular disease (CVD) risk have been well recognised since the advent of effective treatments, including the HMG-CoA reductase inhibitors (statins). Use of statins is likely to have been a contributory factor in the fall of over 75% in CVD mortality in many industrialised countries over the last 40 years. Other interventions, including improved management of other cardiovascular risk factors, notably hypertension and smoking, have also been important. However, CVD continues to be responsible for one in four premature deaths in the UK, with rates in the most deprived 10% of the population being almost twice as high as in least deprived cohorts. 
Category: Editorial
Tuesday, 03 October 2017
A number of new and updated guidelines were launched at the recent European Society of Cardiology congress in Barcelona.
Category: Have You Heard
Wednesday, 21 February 2018
NHS RightCare is a national NHS England-supported programme helping to ensure that the best possible care is delivered as efficiently as possible, and that this care is right for patients and will help ensure a sustainable NHS, now and for the future.
Category: Editorial
Wednesday, 30 May 2018
New research from Sweden presented at the recent European Congress on Obesity, shows that bariatric surgery is associated with a 61% fall in the risk of developing malignant melanoma skin cancer, and a 42% drop in the risk of skin cancer in general.
Thursday, 04 October 2018
The most extensive systematic assessment of effects of omega‐3 fats on cardiovascular health to date suggests that increasing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has little or no effect on mortality or cardiovascular health.
Friday, 02 August 2019
Community pharmacists are widely recognised as an under-utilised resource within the NHS, in spite of their skills and experience, and the accessibility of their premises. In recent years, community pharmacists have demonstrated the value of the clinical services they offer, particularly in the prevention of cardiovascular disease (CVD).
Category: Editorial
Thursday, 08 August 2019
We know that there are differences in outcomes between populations that cannot be explained by the dictates of evidence-based medicine or by demographics. Core to the work of NHS RightCare is the concept of unwarranted variation and the vital importance of using our shared NHS resources to deliver the best outcomes for our population. In 2018, NHS RightCare developed the toolkit for physical ill health and cardiovascular disease (CVD) prevention in people with severe mental illness (SMI), in close collaboration with Public Health England (PHE).
Category: Editorial
Thursday, 08 August 2019
In 2017 the University of Sheffield was commissioned by Public Health England (PHE) to develop a new return on investment (ROI) tool for cardiovascular disease (CVD) prevention, to be used by national and local decision-makers. The tool focuses on prevention of CVD in six key high-risk groups, identified through the NHS RightCare pathway as being currently underdiagnosed and insufficiently well managed. This includes patients with hypertension, diabetes (type 1 and type 2), non-diabetic hyperglycaemia, atrial fibrillation, chronic kidney disease and high cholesterol (the latter including patients with a QRISK2 score ≥ 10% or familial hypercholesterolaemia).
Category: Editorial
Thursday, 08 August 2019
Cardiovascular disease (CVD) prevention has been highlighted by the Next Steps on the Five Year Forward View as a key priority for clinical commissioning groups (CCGs). An important area of focus is improving the management of high-risk conditions for CVD, such as atrial fibrillation (AF). In response to this escalating healthcare priority, Imperial College Health Partners have developed the new AF High Impact Intervention Tool in collaboration with NHS RightCare, as part of their CVD Prevention Pathway.
Category: Editorial
Monday, 08 April 2019
Our regular Evidence in Practice feature summarizes recent scientific papers focusing on different aspects of cardiovascular medicine. This month we feature recent research showing that anti-inflammatory biological drugs used to treat severe psoriasis have the potential to prevent heart in patients with the condition. Over one year of treatment, biological therapy improved coronary artery plaques in a manner similar to a low-dose statin.
Page 3 of 4

Article search and filter